Adnan Yousuf
Family Medicine · Houston, TXNPI 1841347242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Abbott at 32.1% of the total. Reporting peaked in 2020 at $427 and has fallen 93.1% since, to $29 in 2024.
Across 55 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$384
- GSK$166
- Boehringer Ingelheim$126
- AbbVie$96
- Novo Nordisk$68
- Sanofi-aventis U.S. LLC$55
- plus $301 from 12 others
Across 5 payments — averaging $12,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$39K
- AstraZeneca$25K
What the payments were for
- Food & beverage$1,196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $384 |
| GSK | 10 | $166 |
| Boehringer Ingelheim | 6 | $126 |
| AbbVie(2 entities) | 7 | $96 |
| Novo Nordisk | 5 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Astellas Pharma US Inc | 4 | $51 |
| Pfizer | 3 | $46 |
| Medtronic | 1 | $43 |
| Mylan Specialty L.p. | 2 | $33 |
| Johnson & Johnson | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Amgen | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,196 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $114,706 |
| OzempicSemaglutide | 72 | $106,524 |
| JardianceEmpagliflozin | 38 | $47,373 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $36,216 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $32,804 |
| TradjentaLinagliptin | 29 | $29,048 |
| MyrbetriqMirabegron | 30 | $26,747 |
| EntrestoSacubitril/Valsartan | 20 | $25,977 |
| LinzessLinaclotide | 26 | $24,489 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $17,092 |
| XareltoRivaroxaban | 22 | $16,504 |
| FarxigaDapagliflozin Propanediol | 12 | $14,861 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,928 |
| Spiriva HandihalerTiotropium Bromide | 17 | $12,886 |
| MounjaroTirzepatide | 11 | $11,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $114,706139 claims |
| Novo NordiskOzempic | $68 | $106,52472 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $126 | $83,18981 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $166 | $55,54074 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $26,74730 claims |
| NovartisEntresto | $14 | $25,97720 claims |
| AstraZenecaFarxiga, Brilinta | $12 | $25,11836 claims |
| AbbVieLinzess | $96 | $24,48926 claims |
| Johnson & JohnsonXarelto | $25 | $16,50422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Shannon SchraderHouston$216K
- Candice WinfulHouston$173K
- Guljeet SohalHouston$72K
- Lakecia PittsHouston$71K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.